Lupus Nephritis clinical trials

Explore recruiting lupus nephritis clinical trials.

Recruiting lupus nephritis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Lupus Nephritis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Obinutuzumab for systemic lupus erythematosus pure membranous nephropathy: a phase II trial (OBLUMEN)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Dose Escalation Study with Bispecific Antibodies in Adult Patients with Lupus Nephritis

Spain, France, Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

An open-label extension study to assess the efficacy and safety of ianalumab with or without study treatment withdrawal in adult participants with lupus nephritis who have completed study treatment in the CVAY736K12301 core study (SIRIUS-LN extension)

Hungary, Romania, Czechia, France, Spain, Lithuania

Therapeutic confirmatory (Phase III) EU CTIS Study details

Assessing residual inflammation and macrophage presence in lupus nephritis after 3 months of intensified treatment with prednisolone, mycofenolate mofetil and voclosporin as compared to mycofenolate mofetil and prednisolone: an open label randomized controlled trial (MAPLE study)

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

“A Phase II, double-blinded, placebo-controlled clinical trial to evaluate the safety and efficacy of mesenchymal cells (MSV-ALLO®) in the treatment of lupus nephritis”

Spain

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Lupus Nephritis (KYSA-3)

Germany

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Lupus Nephritis trials by city

Lupus Nephritis in Toronto Lupus Nephritis in Vancouver Lupus Nephritis in Montreal Lupus Nephritis in Calgary Lupus Nephritis in Edmonton Lupus Nephritis in Ottawa Lupus Nephritis in Winnipeg Lupus Nephritis in Quebec City Lupus Nephritis in Hamilton Lupus Nephritis in Kitchener Lupus Nephritis in London Lupus Nephritis in Halifax Lupus Nephritis in New York Lupus Nephritis in Los Angeles Lupus Nephritis in Chicago Lupus Nephritis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease